InsiderDB

SEC EDGAR · Company announcement

ZYME: Material agreement · Company disclosure

Filed 8-K for an event or period dated 2026-10-22. Material agreement; Company disclosure.

Follow ZYME
Became public
Oct 23, 2026, 6:07 AM EDT
Event / period date
Oct 22, 2026
Collected
Nov 16, 2026, 6:37 AM EST

Why this is connected

This filing identifies Zymeworks Inc. as the issuer of the security. The company's SEC identifier connects it to ZYME.

Press Release dated ↗

Source evidence

Read the source excerpt or record
ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT On October 22, 2026, Zymeworks Inc. and its subsidiary Zymeworks BC Inc. (together, the “Company”) entered into a Collaboration and License Agreement (the “Collaboration and License Agreement”) with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, “Roche”), granting Roche exclusive rights to develop and commercialize the Company’s proprietary trispecific T-cell engager targeting DLL3-expressing tumor cells product candidate known as ZW209 (“ZW209”) throughout the world. License . Under the terms of the Collaboration and License Agreement, the Company granted to Roche an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, under certain of the Company’s intellectual property, to research, develop, make, have made, use, sell, offer for sale, import, export, and otherwise exploit pharmaceutical products, including any combination product, containing (i) ZW209, (ii) any other trispecific T-cell engagers targeting DLL3-expressing tumor cells that are covered by any intellectual property owned or controlled by the Company as of the Effective Date (as defined below), or (iii) any derivatives, modifications or a back-up compound of the foregoing (each a “Compound”), as a pharmaceutically active ingredient, regardless of its finished forms, formulations, or dosages (“Products”), and companion diagnostics for such Products. The license granted by the Company will become effective on the first business day (the “Effective Date”) after receipt of clearance relating to the United States Hart-Scott Rodino Antitrust Improvements Act of 1976 (“HSR Clearance”). Exclusivity . From the Effective Date until the earlier of (i) five years, (ii) initiation of the first Phase 3 study for the f

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.